Literature DB >> 31527129

Entamoeba histolytica Interaction with Enteropathogenic Escherichia coli Increases Parasite Virulence and Inflammation in Amebiasis.

Luz A Fernández-López1, Karla Gil-Becerril1, Silvia Galindo-Gómez1, Teresa Estrada-García2, Cecilia Ximénez3, Aralia Leon-Coria4, France Moreau4, Kris Chadee5, Víctor Tsutsumi6.   

Abstract

Epidemiological studies suggest frequent association of enteropathogenic bacteria with Entamoeba histolytica during symptomatic infection. In this study, we sought to determine if the interaction with enteropathogenic (EPEC) or nonpathogenic Escherichia coli (strain DH5α) could modify the virulence of E. histolytica to cause disease in animal models of amebiasis. In vitro studies showed a 2-fold increase in CaCo2 monolayer destruction when E. histolytica interacted with EPEC but not with E. coli DH5α for 2.5 h. This was associated with increased E. histolytica proteolytic activity as revealed by zymogram analysis and degradation of the E. histolytica CP-A1/5 (EhCP-A1/5) peptide substrate Z-Arg-Arg-pNC and EhCP4 substrate Z-Val-Val-Arg-AMC. Additionally, E. histolytica-EPEC interaction increased EhCP-A1, -A2, -A4, and -A5, Hgl, Apa, and Cox-1 mRNA expression. Despite the marked upregulation of E. histolytica virulence factors, nonsignificant macroscopic differences in amebic liver abscess development were observed at early stages in hamsters inoculated with either E. histolytica-EPEC or E. histolytica-E. coli DH5α. Histopathology of livers of E. histolytica-EPEC-inoculated animals revealed foci of acute inflammation 3 h postinoculation that progressively increased, producing large inflammatory reactions, ischemia, and necrosis with high expression of il-1β, ifn-γ, and tnf-α proinflammatory cytokine genes compared with that in livers of E. histolytica-E. coli DH5α-inoculated animals. In closed colonic loops from mice, intense inflammation was observed with E. histolytica-EPEC manifested by downregulation of Math1 mRNA with a corresponding increase in the expression of Muc2 mucin and proinflammatory cytokine genes il-6, il-12, and mcp-1 These results demonstrate that E. histolytica/EPEC interaction enhanced the expression and production of key molecules associated with E. histolytica virulence, critical in pathogenesis and progression of disease.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Entamoeba histolyticazzm321990; Escherichia colizzm321990; amebic liver abscess; enteropathogenic; intestinal amebiasis; liver abscess; virulence; virulence factors

Mesh:

Substances:

Year:  2019        PMID: 31527129      PMCID: PMC6867848          DOI: 10.1128/IAI.00279-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  Prostaglandin E2 produced by Entamoeba histolytica signals via EP4 receptor and alters claudin-4 to increase ion permeability of tight junctions.

Authors:  Manigandan Lejeune; France Moreau; Kris Chadee
Journal:  Am J Pathol       Date:  2011-05-31       Impact factor: 4.307

2.  The mouse model of amebic colitis reveals mouse strain susceptibility to infection and exacerbation of disease by CD4+ T cells.

Authors:  Eric R Houpt; David J Glembocki; Tom G Obrig; Christopher A Moskaluk; Lauren A Lockhart; Rhonda L Wright; Regina M Seaner; Tiffany R Keepers; Tracy D Wilkins; William A Petri
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

Review 3.  Pathogenesis of intestinal amebiasis: from molecules to disease.

Authors:  M Espinosa-Cantellano; A Martínez-Palomo
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

4.  The pathogenesis of experimentally induced amebic liver abscess in the gerbil (Meriones unguiculatus).

Authors:  K Chadee; E Meerovitch
Journal:  Am J Pathol       Date:  1984-10       Impact factor: 4.307

5.  Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa.

Authors:  Kirk S B Bergstrom; Vanessa Kissoon-Singh; Deanna L Gibson; Caixia Ma; Marinieve Montero; Ho Pan Sham; Natasha Ryz; Tina Huang; Anna Velcich; B Brett Finlay; Kris Chadee; Bruce A Vallance
Journal:  PLoS Pathog       Date:  2010-05-13       Impact factor: 6.823

6.  Synergy between Entamoeba histolytica and Escherichia coli in the induction of cytokine gene expression in human colon epithelial cells.

Authors:  J M Kim; H C Jung; K I Im; I S Song; C Y Kim
Journal:  Parasitol Res       Date:  1998-06       Impact factor: 2.289

7.  Microbiome-mediated neutrophil recruitment via CXCR2 and protection from amebic colitis.

Authors:  Koji Watanabe; Carol A Gilchrist; Md Jashim Uddin; Stacey L Burgess; Mayuresh M Abhyankar; Shannon N Moonah; Zannatun Noor; Jeffrey R Donowitz; Brittany N Schneider; Tuhinur Arju; Emtiaz Ahmed; Mamun Kabir; Masud Alam; Rashidul Haque; Patcharin Pramoonjago; Borna Mehrad; William A Petri
Journal:  PLoS Pathog       Date:  2017-08-17       Impact factor: 6.823

8.  Defining cooperative roles for colonic microbiota and Muc2 mucin in mediating innate host defense against Entamoeba histolytica.

Authors:  Aralia Leon-Coria; Manish Kumar; France Moreau; Kris Chadee
Journal:  PLoS Pathog       Date:  2018-11-30       Impact factor: 6.823

9.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling.

Authors:  Katia Boniface; Kristian S Bak-Jensen; Ying Li; Wendy M Blumenschein; Mandy J McGeachy; Terrill K McClanahan; Brent S McKenzie; Robert A Kastelein; Daniel J Cua; René de Waal Malefyt
Journal:  J Exp Med       Date:  2009-03-09       Impact factor: 14.307

10.  Enteric bacteria boost defences against oxidative stress in Entamoeba histolytica.

Authors:  Hugo Varet; Yana Shaulov; Odile Sismeiro; Meirav Trebicz-Geffen; Rachel Legendre; Jean-Yves Coppée; Serge Ankri; Nancy Guillen
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

View more
  1 in total

Review 1.  Parasite-bacteria interrelationship.

Authors:  Dalia S Ashour; Ahmad A Othman
Journal:  Parasitol Res       Date:  2020-08-04       Impact factor: 2.289

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.